Psoralen photochemotherapy, clinical efficacy, and photomutagenicity: The role of molecular epidemiology in minimizing risks

Environmental and Molecular Mutagenesis

Volumn 31, Issue 2, 1998, Pages 105-112

  Gasparro, F P ^a   Liao, B ^a   Foley, P J ^a   Wang, X M ^a,c   McNiff, J Madison ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

^c New York Presbyterian Hospital Columbia University Medical Center   (United States)

Author keywords

Melanoma; Mutation; p53; Photoadduct; Psoralen; Psoriasis ; PUVA; Skin cancer

Indexed keywords

PSORALEN;

DRUG EFFICACY; DRUG SAFETY; DRUG TOXICITY; HUMAN; MUTAGENICITY; MUTATION RATE; PHOTOACTIVATION; PHOTOCHEMOTHERAPY; PSORIASIS; PUVA; REVIEW; SKIN CANCER; SQUAMOUS CELL CARCINOMA; TUMOR SUPPRESSOR GENE; ULTRAVIOLET RADIATION;

EPIDEMIOLOGY, MOLECULAR; FICUSIN; GENES, P53; HUMANS; MUTAGENESIS; PHOTOSENSITIZING AGENTS; POINT MUTATION; PUVA THERAPY; RISK ASSESSMENT; TREATMENT OUTCOME;

MURINAE;

EID: 0031958530     PISSN: 08936692     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2280(1998)31:2<105::AID-EM2>3.0.CO;2-L     Document Type: Review

References (44)

1. Averbeck D, Papadopoulo D (1986): Genetic effects of DNA mono-and diadducts photoinduced by furocoumarins in eukaryotic cells. IARC Sci Publ 70:299-312.
2. Averbeck D, Chandra P, Biswas RK (1975): Structural specificity in the lethal and mutagenic activity of furocoumarins in yeast cells. Radiat Environ Biophys 12:241-252.
3. Ben-Hur E, Elkind MM (1973): Psoralen plus near ultraviolet light inactivation of cultured Chinese hamster cells and its relation to DNA cross-links. Mutat Res 18:315-324.
4. Boyer V, Moustacchi E, Sage E (1988): Sequence specificity in photoreaction of various psoralen derivatives with DNA: Role in biological activity Biochemistry 27:3011-3018.
5. Brash DE, Rudolph JA, Simon JA, Lin A, McKenna GJ, Baden HP, Halperin AJ, Ponten J (1991): A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 88:10124-10128.
6. Bredberg A, Nachmansson N (1987): Psoralen adducts in a shuttle vector plasmid propagated in primate cells: High mutagenicity of DNA cross-links. Carcinogenesis 8:1923-1927.
7. Burger PM, Simons JWIM (1979): Mutagenicity of 8-methoxypsoralen and long-wave ultraviolet irradiation in haploid human skin fibroblasts: An improved risk estimate in photochemotherapy. Mutat Res 63:371-380.
8. Cimino GD, Camper HB, Isaacs ST, Hearst JE (1985): Psoralens as photoactive probes of nucleic acid structure and function: Organic chemistry, photochemistry, and biochemistry. Annu Rev Biochem 54:1151-1193.
9. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ (1993): Gain of function mutations in p53. Nat Genet 4:42-46.
10. Edelson R, Berger C, Gasparro F, Jegasothy B, Heald P, Wintroub B, Vonderheid E, Knobler R, Wolff K, Plewig G et al. (1987): Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 316:297-303.
11. Fields S, Jang SK (1990): Presence of a potent transcription activating sequence in the p53 protein. Science 249:1046-1049.
12. Frederiksen S, Hearst JE (1979): Binding of 4′-aminomethyl 4,5′,8-trimethylpsoralen to DNA, RNA and protein in HeLa cells and Drosophila cells. Biochim Biophys Acta 563:343-355.
13. Greenblatt MS, Bennett WP, Hollstein M, Harris CC (1994): Mutations in p53 tumor suppression gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res 54:4855-4878.
14. Gunther EJ, Yeasky TM, Gasparro FP, Glazer PM (1995): Mutagenesis by 8-methoxypsoralen and 5-methylangelicin photoadducts in mouse fibroblasts: Mutations at cross-linkable sites induced by adducts as well as cross-links. Cancer Res 55:1283-1288.
15. Hart RW, Setlow RB (1974): The correlation between deoxyribonucleic acid excision-repair and life-span in a number of mammalian species. Proc Natl Acad Sci USA 71:2169-2173.
16. Honigsmann H (1986): Psoralen photochemotherapy - mechanisms, drugs, toxicity. Curr Probl Dermatol 15:52-66.
17. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, Leffell DK, Tarone RE, Brash DE (1996): Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 93:14025-14029.
18. Kim SH, Tomic MT, Wemmer DE, Pearlman D, Holbrook S (1988): Structure of DNA damaged by UV and psoralen. Biochem Pharmacol 37:1791.
19. Krueger JG, Wolfe JT, Nabeya RT, Vallat VP, Gilleaudeau P, Heftler NS, Austin LM, Gottlieb AB (1995): Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratino-cyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 182:2057-2068.
20. Levin DE, Hollstein M, Christman MF, Schwiers EA, Ames BN (1982): A new Salmonella tester strain (TA102) with A X T base pairs at the site of mutation detects oxidative mutagens. Proc Natl Acad Sci USA 79:7445-7449.
21. Lindelof B, Sigurgeirsson B (1993): PUVA and cancer: A case-control study. Br J Dermatol 129:39-41.
22. Moor ACE, Gasparro FP (1996): Biochemical aspects of psoralen photochemotherapy. Clin Dermatol 4:353-356.
23. Musajo L, Rodighiero G, Breccia A, Dall'Acqua F (1968): The photoreaction between DNA and the skin-photosensitizing furocoumarin studied using labeled bergapten. Experientia 22:75.
24. Nataraj AJ, Black HS, Ananthaswamy HN (1996): Signature p53 mutation at DNA cross-linking sites in 8-methoxypsoralen and ultraviolet A (PUVA)-induced murine skin cancers. Proc Natl Acad Sci USA 93:7961-7965.
25. Nataraj AJ, Wolf P, Cerroni L, Ananthaswamy HN (1997): p53 mutation in squamous cell carcinomas from psoriasis patients treated with psoralen + UVA (PUVA). J Invest Dermatol 109:238-243.
26. Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA (1974): Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med 291:1207-1211.
27. Perry ME, Pettite J, Zawadzki JA, Levine AJ (1993): The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci USA 90:11623-11627.
28. Pierceall WE, Kripke ML, Ananthaswamy HN (1992): N-ras mutation in ultraviolet radiation-induced murine skin cancers. Cancer Res 52:3946-3951.
29. Sage E, Boyer V, Moustacchi E (1988): Sequence specificity in psoralen-DNA photobinding. Biochem Pharmacol 37:1829-1830.
30. Sage E, Drobetsky EA, Moustacchi E (1993): 8-Methoxypsoralen induced mutations are highly targeted at crosslinkable sites of photoaddition on the non-transcribed strand of a mammalian chromosomal gene. EMBO J 12:397-402.
31. Sagher D, Strauss B (1983): Insertion of nucleotides opposite apurinic/ apyrimidinic sites in deoxyribonucleic acid during in vitro synthesis: Uniqueness of adenine nucleotides. Biochemistry 22: 4518-4526.
32. Schmitt IM, Maxwell VM, Edelson RL, Chimenti S, Gasparro FP (1994): The specific effects of 8-methoxypsoralen photoadducts on cell growth: HPLC analysis of monoadduct and crosslink formation in cells exposed to split-dose treatment. J Photochem Photobiol B, 22:17-21.
33. Stern RS, Laird N, Members of the Photochemotherapy Follow-up Study (1994): The carcinogenic risk of treatments for severe psoriasis. Cancer 73:2759-2764.
34. Stern RS, Nichols KT, Väkevä LH, for the PUVA Follow-up Study (1997): Malignant melanoma inpatients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). N Engl J Med 336:1041-1045.
35. Strauss GH, Albertini RJ, Krusinski PA, Baughman RD (1979): 6-Thioguanine resistant peripheral blood lymphocytes in humans following psoralen, long-wave ultraviolet light (PUVA) therapy. J Invest Dermatol 73:211-216.
36. Studniberg HM, Weller P (1993): PUVA, UVB, psoriasis, and nonmelanoma skin cancer. J Am Acad Dermatol 29:1013-1022.
37. Tessman JW, Isaacs ST, Hearst JE (1985): Photochemistry of the furan-side 8-methoxy-psoralen-thymidine monoadduct inside the DNA helix. Conversion to diadduct and to pyrone-side monoadduct. Biochemistry 24:1669-1676.
38. Tokura Y, Edelson RL, Gasparro FP (1991): Formation and removal of 8-MOP-DNA photoadducts in keratinocytes: Effects of calcium concentration and retinoids. J Invest Dermatol 96:942-949.
39. Ueda H, Ullrich SJ, Gangemi JD, Rappel CA, Ngo L, Feitelson MA, Jay G (1995): Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 9:41-47.
40. Vallat VP, Gilleaudeau P, Battat L, Wolfe J, Nabeya R, Heftler N, Hodak E, Gottlieb AB, Krueger JG (1994): PUVA bath therapy strongly suppresses immunological epidermal activation in psoriasis: A possible cellular basis for remittive therapy. J Exp Med 180:283-296.
41. Wrone-Smith T, Johnson T, Nelson B, Boise LH, Thompson CB, Nunez G, Nickoloff BJ (1995): Discordant expression of bcl-x and bcl-2 by keratinocytes in vitro and psoriatic keratinocytes in vivo. Am J Pathol 146:1079-1088.
42. Yang SC, Lin JG, Chiou CC, Chen LY, Yang JL (1994): Mutation specificity of 8-methoxypsoralen plus two doses of UVA irradiation in the hprt gene in diploid human fibroblasts. Carcinogenesis 15:201-207.
43. Yun MH, Choi SJ, Shim SC (1992): A novel photoadduct of 4,5′,8-trimethylpsoralen and adenosine. Photochem Photobiol 55:457-460.
44. Wang XM, McNiff JM, Klump V, Asgari M, Gasparro FP (1997): An unexpected spectrum of p53 mutations from squamous cell carcinomas in patients treated with PUVA. Photochem Photobiol 66:294-299.